» Articles » PMID: 22580331

A Novel Regulator of Macrophage Activation: MiR-223 in Obesity-associated Adipose Tissue Inflammation

Overview
Journal Circulation
Date 2012 May 15
PMID 22580331
Citations 228
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Macrophage activation plays a crucial role in regulating adipose tissue inflammation and is a major contributor to the pathogenesis of obesity-associated cardiovascular diseases. On various types of stimuli, macrophages respond with either classic (M1) or alternative (M2) activation. M1- and M2-mediated signaling pathways and corresponding cytokine production profiles are not completely understood. The discovery of microRNAs provides a new opportunity to understand this complicated but crucial network for macrophage activation and adipose tissue function.

Methods And Results: We have examined the activity of microRNA-223 (miR-223) and its role in controlling macrophage functions in adipose tissue inflammation and systemic insulin resistance. miR-223(-/-) mice on a high-fat diet exhibited an increased severity of systemic insulin resistance compared with wild-type mice that was accompanied by a marked increase in adipose tissue inflammation. The specific regulatory effects of miR-223 in myeloid cell-mediated regulation of adipose tissue inflammation and insulin resistance were then confirmed by transplantation analysis. Moreover, using bone marrow-derived macrophages, we demonstrated that miR-223 is a novel regulator of macrophage polarization, which suppresses classic proinflammatory pathways and enhances the alternative antiinflammatory responses. In addition, we identified Pknox1 as a genuine miR-223 target gene and an essential regulator for macrophage polarization.

Conclusion: For the first time, this study demonstrates that miR-223 acts to inhibit Pknox1, suppressing proinflammatory activation of macrophages; thus, it is a crucial regulator of macrophage polarization and protects against diet-induced adipose tissue inflammatory response and systemic insulin resistance.

Citing Articles

Development of a macrophage polarization-modulating therapeutic agent for osteoarthritis treatment.

Wu L, Cao X, Shen B J Orthop Surg Res. 2025; 20(1):279.

PMID: 40082923 PMC: 11908040. DOI: 10.1186/s13018-025-05679-2.


Cellular Phenotypic Transformation During Atherosclerosis: The Potential Role of miRNAs as Biomarkers.

Wassaifi S, Kaeffer B, Zarrouk S Int J Mol Sci. 2025; 26(5).

PMID: 40076710 PMC: 11900927. DOI: 10.3390/ijms26052083.


Metabolic Messengers: small extracellular vesicles.

Rohm T, Cunha E Rocha K, Olefsky J Nat Metab. 2025; 7(2):253-262.

PMID: 39920357 DOI: 10.1038/s42255-024-01214-5.


MicroRNAs as Biomarkers for Metabolic Disorders in Polycystic Ovary Syndrome (PCOS): A Review.

Dymanowska I, Frankowska K, Krawczyk A, Kociuba J, Gil-Kulik P, Banaszewska B Med Sci Monit. 2024; 30:e946480.

PMID: 39709519 PMC: 11670786. DOI: 10.12659/MSM.946480.


MicroRNAs as Epigenetic Regulators of Obesity.

Engin A, Engin A Adv Exp Med Biol. 2024; 1460:595-627.

PMID: 39287866 DOI: 10.1007/978-3-031-63657-8_20.